BioNTech SE

General Information
Business:

 

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and that in order to effectively address this challenge, we must create individualized treatments for each patient. We and our collaborators have advanced a development pipeline of over 20 product candidates, of which eight have entered into nine ongoing clinical trials. While we believe our approach is broadly applicable across a number of therapeutic areas, our most advanced programs are focused on oncology, where we have treated over 250 patients across 17 tumor types to date. Our immunotherapy drug classes consist of messenger ribonucleic acid, or mRNA, therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators. Our product candidates span oncology, infectious diseases and rare diseases.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 1100
Founded: 2008
Contact Information
Address An der Goldgrube 12, D-55131 Mainz, Germany
Phone Number +49 6131-9084-0
Web Address http://www.biontech.de
View Prospectus: BioNTech SE
Financial Information
Market Cap $3393.9mil
Revenues $149.8 mil (last 12 months)
Net Income $-127.2 mil (last 12 months)
IPO Profile
Symbol BNTX
Exchange NASDAQ
Shares (millions): 10.0
Price range $15.00 - $15.00
Est. $ Volume $150.0 mil
Manager / Joint Managers J.P. Morgan/ BofA Merrill Lynch/ UBS Investment Bank/ SVB Leerink
CO-Managers Canaccord Genuity/ Bryan, Garnier/ Berenberg/ Wolfe Capital Markets and Advisory/ Kempen/ Mirae Asset Securities
Expected To Trade: 10/10/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change